Pharmacokinetics of triple-combination antihypertensive drugs. Active substance profiles following oral administration and 24-hour blood pressure control Review article

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Oct 20, 2026
DOI: https://doi.org/10.24292/01.MF.0226.17
Keywords:
arterial hypertension, single-pill combinations, SPC, pharmacokinetics, half-life, steady state

Main Article Content

Wioletta Dyrla
Katedra i Klinika Kardiologii, Chorób Wewnętrznych i Nadciśnienia Tętniczego, Warszawski Uniwersytet Medyczny; Mazowiecki Szpital Bródnowski w Warszawie
Marek Kuch
Katedra i Klinika Kardiologii, Chorób Wewnętrznych i Nadciśnienia Tętniczego, Warszawski Uniwersytet Medyczny; Mazowiecki Szpital Bródnowski w Warszawie

Abstract

Triple single-pill combinations (SPCs) bring together substances with markedly different pharmacokinetic profiles. This paper reviews three combinations used in arterial hypertension: perindopril arginine + indapamide + amlodipine, telmisartan + amlodipine + hydrochlorothiazide, and amlodipine + valsartan + hydrochlorothiazide. For each substance, Tmax, half-life, bioavailability, absorption and elimination, food effect and time to steady state are presented, together with modelled concentration-time curves after a single dose and during repeated dosing. Each combination shows the same kinetic complementarity: a short-Tmax component provides rapid onset, while a long half-life component sustains exposure to the end of the 24-hour dosing interval.

Article Details

How to Cite
Dyrla, W., & Kuch, M. (2026). Pharmacokinetics of triple-combination antihypertensive drugs. Active substance profiles following oral administration and 24-hour blood pressure control. Medycyna Faktow (J EBM), 19(2(71), 267-273. https://doi.org/10.24292/01.MF.0226.17
Issue
Vol 19 No 2(71) (2026)
Section
Articles

Copyright by Medical Education. All rights reserved.

References

1. Charakterystyka Produktu Leczniczego. CoAramlessa (peryndopryl z argininą + indapamid + amlodypiny bezylan), pkt 5.1–5.2, KRKA d.d. Novo mesto; data zatwierdzenia ChPL: 27.05.2025.
2. Charakterystyka Produktu Leczniczego, Tolutris (telmisartan + amlodypina + hydrochlorotiazyd), pkt 5.1–5.2, KRKA d.d. Novo mesto; data zatwierdzenia ChPL: 20.09.2025.
3. Charakterystyka Produktu Leczniczego. Valtricom (amlodypina + walsartan + hydrochlorotiazyd), pkt 5.1–5.2, KRKA d.d. Novo mesto; data zatwierdzenia ChPL: 14.02.2026.
4. Patel A; ADVANCE Collaborative Group; MacMahon S, Chalmers J, Neal B et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370(9590): 829-40.
5. ONTARGET Investigators; Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358(15): 1547-59.
6. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288(23): 2981-97.